KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to -$3.6 million.

  • West Pharmaceutical Services' Exchange Rate Effect fell 13243.24% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $700000.0, marking a year-over-year decrease of 9556.96%. This contributed to the annual value of -$21.4 million for FY2024, which is 28771.93% down from last year.
  • West Pharmaceutical Services' Exchange Rate Effect amounted to -$3.6 million in Q3 2025, which was down 13243.24% from $18.5 million recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' Exchange Rate Effect ranged from a high of $38.8 million in Q4 2022 and a low of -$24.1 million during Q3 2022
  • In the last 5 years, West Pharmaceutical Services' Exchange Rate Effect had a median value of -$2.6 million in 2021 and averaged -$673684.2.
  • As far as peak fluctuations go, West Pharmaceutical Services' Exchange Rate Effect tumbled by 64324.32% in 2022, and later surged by 178181.82% in 2025.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Exchange Rate Effect stood at -$2.6 million in 2021, then soared by 1592.31% to $38.8 million in 2022, then crashed by 62.63% to $14.5 million in 2023, then tumbled by 256.55% to -$22.7 million in 2024, then soared by 84.14% to -$3.6 million in 2025.
  • Its Exchange Rate Effect stands at -$3.6 million for Q3 2025, versus $18.5 million for Q2 2025 and $8.5 million for Q1 2025.